Výsledky vyhledávání

Pevonedistat, a NEDD8-activating enzyme inhibitor, is active in mantle cell lymphoma and enhances rituximab activity in vivo

Autor: Cory Mavis, Natalie M Czuczman, Juan Gu, Song Liu, Francisco J. Hernandez-Ilizaliturri, Pavel Klener, Myron S. Czuczman, Qiang Hu, Sarah Frys, Petra Vockova, Matthew J. Barth, Vishala T. Neppalli

Publikováno v: Blood. 127:1128-1137

Mantle cell lymphoma (MCL) is characterized by an aggressive clinical course and inevitable development of refractory disease, stressing the need to develop alternative therapeutic strategies. To this end, we evaluated pevonedistat (MLN4924), a novel

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::5418a5bd52eef94352c0e3dd98ee3b6f
https://doi.org/10.1182/blood-2015-04-640920

Zobrazit plný text záznamu

Entinostat, a novel histone deacetylase inhibitor is active in B-cell lymphoma and enhances the anti-tumour activity of rituximab and chemotherapy agents

Autor: Joseph J. Skitzki, Juan J Gu, Matthew J. Barth, Liu Song, Qiang Hu, Myron S. Czuczman, Sarah Frys, Cory Mavis, Francisco J. Hernandez-Ilizaliturri, Zachary Simons

Publikováno v: British journal of haematology. 169(4)

Histone deacetylases (HDACs) inhibitors are active in T-cell lymphoma and are undergoing pre-clinical and clinical testing in other neoplasms. Entinostat is an orally bioavailable class I HDAC inhibitor with a long half-life, which is under evaluatio

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::d50163032ba9b377ab8f04bddc21f53f
https://pubmed.ncbi.nlm.nih.gov/25712263

Zobrazit plný text záznamu

Deregulation of the PI3K/Akt Signal Transduction Pathway Is Associated with the Development of Chemotherapy Resistance and Can be Effectively Targeted to Improve Chemoresponsiveness in Burkitt Lymphoma Pre-Clinical Models

Autor: Sarah Frys, Cory Mavis, Rodney R. Miles, Matthew J. Barth, Aradhana Awasthi Tiwari, Natalie M Czuczman, Megan S. Lim, Delphine Rolland, Mitchell S. Cairo

Publikováno v: Blood. 124:1769-1769

Multi-agent chemotherapy regimens have significantly improved long-term survival of pediatric Burkitt Lymphoma (BL) to over 80%. However, patients with refractory or relapsed disease have a dismal prognosis, stressing the need to identify mechanisms

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::495be8590fa8601c083b65d184cc82f4
https://doi.org/10.1182/blood.v124.21.1769.1769

Zobrazit plný text záznamu

MLN4924, An Investigational Inhibitor Of NEDD8 Activating Enzyme (NAE), Is Active In Mantle Cell Lymphoma (MCL) Pre-Clinical Models and Enhances Rituximab Activity In Vivo

Autor: Matthew J. Barth, Natalie M Czuczman, Cory Mavis, Myron S. Czuczman, Sarah Frys, Francisco J. Hernandez-Ilizaliturri, Pavel Klener

Publikováno v: Blood. 122:647-647

MCL is characterized by an aggressive clinical course and inevitable development of refractory disease despite early interventions that include immunotherapy (i.e. rituximab), multi-agent induction chemotherapy (that contains high-dose cytarabine or

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::09343a46e868b8854f7064a90eba55d1
https://doi.org/10.1182/blood.v122.21.647.647

Zobrazit plný text záznamu

The Acquirement Of Rituximab Resistance Is Associated With De-Regulation Of The PI3K/Akt/mTOR Signaling Pathway Leading To Chemotherapy Resistance In Burkitt Lymphoma Pre-Clinical Models

Autor: Myron S. Czuczman, Sarah Frys, Delphine Rolland, Mitchell S. Cairo, Francisco J. Hernandez-Ilizaliturri, Cory Mavis, Megan S. Lim, Andrew Skomra, Natalie M Czuczman, Aradhana Awasthi, Matthew J. Barth

Publikováno v: Blood. 122:5144-5144

Treatment with multi-agent chemotherapy regimens has significantly improved survival in pediatric Burkitt Lymphoma (BL) leading to long-term survival in over 80% of cases. The incorporation of rituximab in the treatment of pediatric B-cell non-Hodgki

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::5a661e833674d9059ec6fe4cd3b282e4
https://doi.org/10.1182/blood.v122.21.5144.5144

Zobrazit plný text záznamu

Entinostat, a Novel Histone Deacetylase (HiDAC) Inhibitor Is Active in B-Cell Lymphoma and Enhances the Anti-Tumor Activity of Rituximab, Chemotherapy Agents and Proteasome Inhibitors

Autor: Francisco J. Hernandez-Ilizaliturri, Cory Mavis, Juan Gu, Matthew J. Barth, Myron S. Czuczman, John F. Gibbs, Sarah Frys

Publikováno v: Blood. 120:1649-1649

Abstract 1649 Deacetylases (DACs) are enzymes that remove the acetyl groups from target protein lysines leading to regulation of gene transcription and other cellular processes. Entinostat is a novel and potent class I DAC inhibitor undergoing pre-cl

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::ef2c19d2a9937d71084d08b6412ef6f7
https://doi.org/10.1182/blood.v120.21.1649.1649

Zobrazit plný text záznamu

Entinostat, a Novel Histone Deacetylase (HiDAC) Inhibitor Enhances the Anti-Tumor Activity of Bortezomib (BTZ) in Rituximab-Chemotherapy Sensitive and Resistant Lymphoma Cell Lines

Autor: John F. Gibbs, Cory Mavis, Juan Gu, Francisco J. Hernandez-Ilizaliturri, Sarah Frys, Myron S. Czuczman

Publikováno v: Blood. 118:3734-3734

Abstract 3734 Deacetylases (DACs) are enzymes that remove the acetyl groups from target proteins [histones (class I) and non-histone proteins (class II)], leading to regulation of gene transcription and other cellular processes. Entinostat (MS-275) i

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::01bbef9db0a3283ff0607fc1b02789ff
https://doi.org/10.1182/blood.v118.21.3734.3734

Zobrazit plný text záznamu

Vyhledávací nástroje:

Upřesnit hledání